NUVL News and Press, Nuvalent Inc. From 09/05/23

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors PR Newswire Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-520 of 100 mg daily CAMBRIDGE, Mass. , ...

Nuvalent to Participate in Upcoming September Investor Conferences PR Newswire CAMBRIDGE, Mass. , Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for ...

2023-08-17 06:40:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks aren’t for everyone. But if you want to dive into a sector that can potentially give you incredible returns, you’ll want to focus your search on A-rated biotech...

2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...

2023-08-10 11:48:16 ET Nuvalent press release ( NASDAQ: NUVL ): Q2 GAAP EPS of -$0.51. Cash, cash equivalents and marketable securities were $431.2 million as of June 30, 2023. R&D Expenses: Research and development (R&D) expenses were $25.9 million for the sec...

Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results PR Newswire Continued execution across pipeline with clinical trials ongoing for NVL-520 and NVL-655, and advancement of NVL-330 toward clinical development Preliminary dose-escalat...

Nuvalent to Participate in Upcoming August Investor Conferences PR Newswire CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clin...

2023-05-25 14:00:55 ET Summary When I say futuristic valuation, I mean a valuation that would be justified if NUVL succeeded in the future. It hasn't yet, so the valuation seems unjustified. The company is doing good science and is managed by Deerfield, a Harvard professor, an...

Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit PR Newswire CAMBRIDGE, Mass. , May 24, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted ther...

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results PR Newswire Preliminary dose-escalation data anticipated in second half of 2023 from ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-...